



Amarin Corporation plc  
Investor Relations Department  
2 Pembroke House, Upper  
Pembroke  
Street 28-32  
Dublin 2  
Ireland

[Visit IR website](#)   
[Sign-up for Email alerts](#)

#### NASDAQ: AMRN

Last Trade:	2.68
Trade Time:	4:00 PM ET Apr 25, 2018
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	2.66 - 4.60
Volume	N/A

Stock information is provided by eSignal,  
stock charts provided by EDGAR Online.  
Stock data is delayed approximately 20  
minutes.

## Company Profile

Amarin is conducting a cardiovascular outcomes study designed to evaluate the efficacy of Vascepa® in reducing cardiovascular events in a high-risk patient population on statin therapy called the REDUCE-IT trial.

Amarin is headquartered in Dublin, Ireland. Amarin's U.S. office is in Bedminster, New Jersey. Amarin is listed in the U.S. on NASDAQ (symbol: "AMRN").

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

*Apr 26, 2018*

[Amarin To Report First Quarter 2018 Results and Host Conference Call On May 2, 2018](#)

*Apr 23, 2018*

[Amarin Announces Promotion of Aaron Berg to Position of Chief Commercial Officer](#)

*Apr 12, 2018*

[Amarin Sponsors Three Scientific Presentations Scheduled for National Lipid Association Scientific Sessions](#)

*Apr 12, 2018*

[Vascepa® \(Icosapent Ethyl\) Showed Reductions in Potentially Atherogenic Lipid and Inflammatory Markers in Statin-Treated Patients with Reduced Kidney Function and Persistent High Triglycerides](#)

*Apr 4, 2018*

[Amarin Updates First Quarter Revenue Guidance, Reiterates Full Year Guidance and Updates on REDUCE-IT Cardiovascular Outcomes Study Progress and Vascepa® Promotion Initiatives](#)

## Financials [\[ View all \]](#)

[Fourth Quarter Financial Results](#)

*Feb 27, 2018*

[Annual Report \(10-K\)](#)

*Apr 20, 2018*

[Proxy Statement \(DEF 14A\)](#)

*Nov 1, 2017*

[Quarterly Report \(10-Q\)](#)

*Aug 2, 2017*

[Quarterly Report \(10-Q\)](#)

*May 3, 2017*

[Quarterly Report \(10-Q\)](#)